Table 2.
Patients’ characteristics, treatment details and response outcomes
| Characteristics | Value |
|---|---|
| Total number of patients, n (%) | 11 (100) |
| Age, median (IQR) | 68 years (62-76) |
| Gleason score at diagnosis, median (IQR) | 8 (7-9) |
| ECOG performance status, n (%) | |
| 0 | 2 (18) |
| 1 | 4 (36) |
| 2 | 5 (46) |
| Prior treatments, n (%) | |
| ADT | 11 (100) |
| Abiraterone | 7 (64) |
| Enzalutamide | 4 (36) |
| Docetaxel | 10 (91) |
| Cabazitaxel | 3 (27) |
| Palliative radiotherapy | 4 (36) |
| 177Lu-PSMA-617 | 5 (46) |
| Bisphosphonate or denosumab | 11 (100) |
| Disease extent at baseline, n (%) | |
| Local nodes | 9 (82) |
| Distant nodes | 3 (27) |
| Skeletal | 11 (100) |
| Visceral | 0 (0) |
| On opioid analgesia for pain | 11 (100) |
| Pretherapy PSA (median, IQR) | 158 (35-840) ng/mL |
| Cumulative activity of 225Ac-PSMA-617, (median, IQR) | 8.3 (5.6-20.4) MBq |
| Number of cycles (range) | 1-4 |
| PSA response, n (%) | |
| PR | 5 (46) |
| SD | 3 (27) |
| PD | 3 (27) |
ADT: Androgen deprivation therapy; ECOG: Eastern cooperation of oncology group; IQR: Interquartile range (1st – 3rd quartiles); PSA: Prostate specific antigen; PD: Progressive disease; PR: Partial response; SD: Stable disease, PSMA: Prostate Specific Membrane Antigen, 225Ac: Actinium-225